BoI Official Confident of Biotechnology Future (Thailand)
This article was originally published in PharmAsia News
Ajarin Pattanapanchai, executive investment adviser for Thailand's Board of Investment, says the emergence of a number of multinational and local companies in the biotechnology business underlines the success of efforts to grow its biotechnology industry. Though Thailand is behind Japan, Singapore, Korea, Malaysia, China, and India in promoting biotechnology, Pattanapanchai points out that the industry depends on personnel with exceptional skills, providing Thailand with an opportunity to catch up by focusing on that area. ''We continue developing and producing personnel from both the state and private educational institutions, especially through strong support from the National Science and Technology Development Agency,'' she says. The entry of multinationals to set up blood banks for special disease diagnosis, stem cell processing, drug production, environmental conservation, and increased productivity for agro-processing industries are all positive signs for the emerging biotech industry. (Click here for more
You may also be interested in...
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.